NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
Pfizer »11/11/2009 [Industry news]
BMP Sunstone Partners with Pfizer to Distribute Endometriosis Treatment in China

BMP Sunstone Corporation and Pfizer China (NYSE: PFE) have formed a strategic partnership to distribute and promote Depo-Provera (Medroxy-progesterone Acetate), a Pfizer product used to treat endometriosis, in China.

 
BMP Sunstone Corporation and Pfizer China (NYSE: PFE) have formed a strategic partnership to distribute and promote Depo-Provera (Medroxy-progesterone Acetate), a Pfizer product used to treat endometriosis, in China. Endometriosis is a medical condition in women of childbearing age that can cause significant pain. Financial details of the agreement were not disclosed. The partnership is interesting because Pfizer has its own drug distribution network in China. But the big pharma decided that in this niche, it could do better by forming an alliance with BMP Sunstone, which has an established line of women’s and infant medical products. BMP acquired the products by buying Sunstone in 2007, which made and distributed the Hao Wawa (Good Baby) brand for children\'s healthcare and Kang Fu Te (Comfort) for women\'s healthcare. After the acquisition, BMP became known as BMP Sunstone. Depo-Provera is already SFDA approved for use in China. Although Pfizer and BMP Sunstone are positioning the product as a treatment for endometriosis, it is also used elsewhere in the world as a medium-term birth control product. Administered as an injection, it is effective for 12 weeks. \"This deal establishes a partnership that utilizes BMP Sunstone\'s unique insight in the women\'s healthcare market, as well as the company\'s proven expertise in marketing niche pharmaceutical products to underserved patient populations in China,\" said Dr. Wu Xiao Bing, Pfizer China Country Manager in a statement. \"We are very excited about our partnership with Pfizer,\" said Mr. Gao Xiao Ying, CEO and Director of BMP Sunstone. \"Depo-Provera is a great addition to our established women\'s health marketing and distribution portfolio in China. The product has already been approved by the China SFDA, and will be immediately marketable -- benefiting many women who suffer from endometriosis. We are expecting to make Depo-Provera one of the cornerstone products at BMP China, and for it to drive our business growth as we introduce it to the marketplace.\"

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.